STOCK TITAN

Pieris Pharmaceu - PIRS STOCK NEWS

Welcome to our dedicated page for Pieris Pharmaceu news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on Pieris Pharmaceu stock.

Pieris Pharmaceuticals, Inc. (PIRS) delivers innovative biopharmaceutical solutions through its proprietary anticalin protein platform. This dedicated news hub provides investors and industry stakeholders with essential updates on clinical developments, strategic collaborations, and therapeutic advancements.

Track critical updates including clinical trial progress in immuno-oncology and respiratory therapies, partnership announcements with global pharmaceutical leaders, and regulatory milestones for novel anticalin-based treatments. Our curated news collection serves as a centralized resource for understanding PIRS's role in advancing precision-targeted therapeutics.

Discover timely updates on pipeline developments across key therapeutic areas and business strategy implementations. This repository is designed to help users monitor the company's progress in translating innovative protein engineering into clinical-stage assets.

Bookmark this page for streamlined access to Pieris Pharmaceuticals' latest announcements and scientific breakthroughs. Regularly updated to ensure you stay informed about this clinical-stage biotech innovator's evolving landscape.

Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) has announced an investor call on March 1, 2022, at 8:00 AM EST to discuss its 2021 financial results and provide a corporate update. Interested participants can join via phone or a webcast. A replay will be available on the company's website. Pieris specializes in developing novel biotherapeutics, including inhalable Anticalin proteins for respiratory diseases and immuno-oncology treatments, supported by their proprietary technology platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) announced the dosing of the first patient in its phase 2 study of cinrebafusp alfa (PRS-343), a bispecific treatment for HER2-expressing gastric cancer. This two-arm study evaluates its efficacy, safety, and tolerability in combination with ramucirumab and paclitaxel or tucatinib. Target outcomes are an overall response rate (ORR) of at least 40% in HER2-low and 50% in HER2-high patients. The company anticipates presenting preliminary data later this year, marking a significant milestone in addressing unmet needs in gastric cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
-
Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) announced the successful completion of the sponsor safety review for part 1a of the phase 2a study of the drug candidate PRS-060/AZD1402, which targets moderate-to-severe asthma. This milestone allows for enrollment of part 2a, focusing on efficacy, and part 1b, assessing high-dose safety. The evaluation involved 31 patients and marked improvements in safety and pharmacokinetics. The primary endpoint for part 2a will be FEV1 improvement compared to placebo. Completion of this study is seen as a significant opportunity for the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) announced participation in two upcoming investor conferences. The Jefferies London Healthcare Conference is scheduled for November 18, 2021 at 8:00 AM GMT, with a webcast available. The 4th Annual Evercore ISI HealthCONx Conference will take place on December 1, 2021 at 11:20 AM EST, also featuring a webcast. Pieris focuses on biotherapeutics for respiratory diseases and cancer through its proprietary Anticalin technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary

Pieris Pharmaceuticals has announced the first patient dosing in the phase 1/2 study of PRS-344/S095012, a bispecific targeting solid tumors. This advance triggers an undisclosed milestone payment from Servier, the company's partner in this clinical trial. PRS-344/S095012 combines 4-1BB-targeting Anticalin proteins and PD-L1-targeting antibodies, showing promising preclinical results in enhancing CD8+ T cell response and extending survival in mouse models. The open-label study will assess safety, tolerability, and anti-tumor activity in patients with advanced solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
-
Rhea-AI Summary

Pieris Pharmaceuticals (PIRS) reported Q3 2021 financial results, showing a net loss of $16.5 million or $(0.24) per share, slightly improved from $(0.26) per share a year prior. The company holds over $125 million in cash, attributed to collaborations, despite rising R&D expenses totaling $18.9 million. Notably, dosing in part 1a of their phase 2a study for PRS-060/AZD1402 has been completed, with topline data expected next year. Pieris also advanced multiple studies, including cinrebafusp alfa and PRS-344. The firm announced executive promotions and partnerships with AstraZeneca, Seagen, and Genentech.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
Rhea-AI Summary

Pieris Pharmaceuticals, a clinical-stage biotechnology company, has announced it will host a third quarter 2021 investor call on November 2, 2021, at 8:00 AM EDT. The call will discuss financial results and provide a corporate update. Participants can dial 877-407-8920 (Toll Free US & Canada) or listen to the webcast. A replay will be available on the company’s website. Pieris focuses on developing Anticalin proteins for respiratory diseases and immuno-oncology, highlighting its innovative approaches in biotherapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
conferences
-
Rhea-AI Summary

Abcuro, Inc., a clinical-stage biotechnology company focused on therapies for autoimmune diseases and cancer, has appointed Darlene Deptula-Hicks to its Board of Directors. With over 30 years of experience in the life sciences sector, she previously served as CFO for several companies, including F-star Therapeutics (NASDAQ:FSTX) and T2 Biosystems (NASDAQ:TTOO). Her expertise in growth strategies and capital raising is expected to boost Abcuro's clinical development initiatives, particularly for its lead program, ABC008, which has received Orphan Drug Designation from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
management
-
Rhea-AI Summary

BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, a clinical-stage biotechnology company, has announced key executive promotions. Thomas Bures has been promoted to Chief Financial Officer, while Ahmed Mousa becomes Chief Business Officer. Bures, with over 20 years of finance experience, focuses on financial strategy, while Mousa will enhance business development and partnerships following his role in closing significant collaborations. The company aims to advance its immuno-oncology and inhaled biologics franchises, pushing towards transformative therapies for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
none
Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) has announced management participation in two upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will take place on September 13, 2021, at 7:00 AM EDT. A webcast is available here. Additionally, the Cantor Global Healthcare Conference is scheduled for September 30, 2021, at 12:00 PM EDT, with a webcast accessible here. Pieris focuses on developing innovative biotherapeutics using its Anticalin technology platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.99%
Tags
conferences
Pieris Pharmaceu

Nasdaq:PIRS

PIRS Rankings

PIRS Stock Data

17.96M
1.30M
0.07%
52.92%
1.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON